Recent Updates
Recently added Catalysts

HTX-011

Phase 3

Analgesia | Small molecule | Pain |Heron Therapeutics, Inc.|Last Updated: Jul 17, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials4
Total Enrollment421

FDA Designations

No designations recorded

Clinical trial landscape

HTX-011 · 12 trials · 4 indications

Phase 3 4Phase 2 8
NCT03974932Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) RegimenAnalgesia
COMPLETED116 Analytics
NCT03907176Study of Post-Herniorrhaphy Non-opioid MMA RegimensAnalgesia
COMPLETED209 Analytics
NCT03295721Bunionectomy Study for Postoperative Analgesia (EPOCH 1)Postoperative Pain
COMPLETED412 Analytics
NCT03237481Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)Postoperative Pain
COMPLETED418 Analytics
PHASE3COMPLETED
Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen
AnalgesiaUnlock trial analytics
PHASE3COMPLETED
Study of Post-Herniorrhaphy Non-opioid MMA Regimens
AnalgesiaUnlock trial analytics
PHASE3COMPLETED
Bunionectomy Study for Postoperative Analgesia (EPOCH 1)
Postoperative PainUnlock trial analytics
PHASE3COMPLETED
Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)
Postoperative PainUnlock trial analytics

Study Endpoints

Primary Endpoints

Mean Area Under the Curve (AUC) of the Visual Analogue Scale (VAS).
12 through 48 hours

The Visual Analog Scale (VAS) consists of a straight 10-cm line that represents pain ranging from "no pain" to "pain as bad as it could be". Subjects were asked to mark their current pain level on the line.

Proportion of Subjects Who do Not Receive an Opioid Prescription Through the Day 15 Visit
Through Day 15
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Saline Placebo.
72 hours

Pain intensity is assessed using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-72 is 0-720. The prescribed activity for NRS-A is sitting with the plantar surface of the ball of the surgically attended foot touching the floor (no weight bearing).

Incidence of Serious Adverse Events
From the time the subject signs the ICF through the Day 29 Visit
Maximum plasma concentration (Cmax) of bupivacaine, meloxicam, dimethyl sulfoxide (DMSO) and HTX-011 polymer
Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
Time of maximum plasma concentration (Tmax) of bupivacaine, meloxicam, DMSO and HTX-011 polymer
Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
Half life (t1/2) in plasma of bupivacaine, meloxicam, DMSO and HTX-011 polymer
Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
Half life (t1/2) in milk of bupivacaine, meloxicam, DMSO and HTX-011 polymer
Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
Amount of analyte excreted in breast milk over time (Ae)
Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
Fraction of dose excreted in breast milk over time (Fe)
Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
Mean Area Under the Curve (AUC) of the NRS-A (Windowed Worst Observation Carried Forward) Pain Intensity Scores
72 hours

Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". NRS scores are recorded with activity (NRS-A), sitting with the plantar surface of the ball of the surgically attended foot touching the floor (no weight-bearing).

Percentage of Subjects Receiving no Opioid Rescue
72 hours
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 24 Hours Postsurgery (AUC0-24).
24 hours

Pain intensity is assessed using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-24 is 0-240. The prescribed activity for NRS-A is keeping the elbows at the side and against the body and then raising both hands in front of the abdomen with hands clasped and holding that position for at least 5 seconds.

Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 48 Hours Postsurgery (AUC0-48).
48 hours

Pain intensity is assessed at rest using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-48 is 0-480.

Mean Summed Pain Intensity (SPI) Score
24 hours

Subjects assessed pain intensity for their current pain with the 11-point (0 to 10) Numeric Rating Scale NRS where "0" equated to "no pain" and "10" equated to "the worst pain imaginable". Pain intensity was assessed at rest (NRS-R) after the subject had been supine for a minimum of 5 minutes and with activity (NRS-A) sitting up from a supine position. The SPI is derived by summing the pain intensity score weighted by the scheduled time duration. SPI0-24 was calculated by summing the Pain intensity (PI) score at the relevant time points weighted by the scheduled time duration since the prior PI assessment as follows: SPI0-24= PI1+PI2+2\*PI4+2\*PI6+2\*PI8+2\*PI10+2\*PI12+2\*PI14+4\*PI18+6\*PI24. Min = 0 (if PI=0 at every time) and Max = 240 (if PI=10 at every time).

SPI0-24
24 hours

Summed Pain Intensity (SPI) Scores over the first 24 hours, which was the sum of the pain intensity scores at the scheduled 1 hour assessment, the assessments scheduled for every 2 hours between Hours 2 and 14, and the assessments scheduled at Hours 18 and 24; with the assessments at Hours 1 and 2 each weighted by 1, the assessments between Hours 4 and 14 each weighted by 2, the assessment at Hour 18 weighted by 4, and the assessment at Hour 24 weighted by 6. Pain was assessed using an 11-point scale, where 0 equaled no pain and 10 equaled the worst pain imaginable. Thus, the minimum and maximum possible SPI0-24 scores were 0 and 240, respectively.

Secondary Endpoints

Mean AUC of VAS Scores.
72 hours
Mean AUC of the NRS of Pain Intensity at Rest (NRS-R).
72 hours
Percentage of Subjects With Severe Pain.
24 hours, 48 hours, 72 hours
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Cohort 1EXPERIMENTALHTX-011 + MMA
Cohort 2EXPERIMENTALHTX-011 + MMA
Cohort 3EXPERIMENTALHTX-011 + MMA
Cohort 4EXPERIMENTALHTX-011 + MMA
HTX-011 + Alternating MMA RegimenEXPERIMENTALHTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen of ibuprofen and acetaminophen, alternating (one or the other every 3 hours), while awake.
HTX-011 + Concurrent MMA RegimenEXPERIMENTALHTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen of ibuprofen and acetaminophen, together every 6 hours, while awake.
Treatment Group 1: HTX-011EXPERIMENTALHTX 011 (bupivacaine/meloxicam)
Treatment Group 2: Saline PlaceboPLACEBO_COMPARATORSaline placebo
Treatment Group 3: Bupivacaine HCIACTIVE_COMPARATORBupivacaine HCl
Treatment Group 2: Bupivacaine HCIACTIVE_COMPARATORBupivacaine HCl
Treatment Group 3: Saline PlaceboPLACEBO_COMPARATORSaline placebo
Cohort 1: Bupivacaine HClEXPERIMENTALBupivacaine HCl without epinephrine, via injection into the surgical site.
Cohort 2: HTX-011EXPERIMENTALHTX-011 (bupivacaine/meloxicam) via application into the surgical site.
Cohort 3: HTX-011EXPERIMENTALHTX-011 (bupivacaine/meloxicam) via application into the surgical site.
Treatment Group 1EXPERIMENTALA single dose of HTX-011 administered via instillation into the surgical site.
Treatment Group 2EXPERIMENTALA single dose of HTX-011 administered via instillation into the surgical site and a scheduled non-opioid multimodal analgesic (MMA) regimen.
Treatment Group 2: HTX-011 + AprepitantEXPERIMENTALHTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation; Aprepitant, three single doses of aprepitant will be administered orally.
Treatment Group 3: HTX-011 + Non-Opioid MMA RegimenEXPERIMENTALHTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation and a scheduled multimodal analgesic (MMA) regimen.
Cohort 1: HTX-011 + MMA RegimenEXPERIMENTALHTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen.
Cohort 2: HTX-011 + MMA Regimen + KetorolacEXPERIMENTALHTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen and IV ketorolac.
Group 1: HTX-011EXPERIMENTALHTX-011 (bupivacaine/meloxicam), 60 mg/1.8 mg via nerve block.
Group 2: HTX-011EXPERIMENTALHTX-011(bupivacaine/meloxicam), 120 mg/3.6 mg via nerve block.
Group 3: HTX-011EXPERIMENTALHTX-011(bupivacaine/meloxicam), 240 mg/7.2 mg via nerve block.
Group 4: HTX-011EXPERIMENTALHTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via nerve block.
Group 5: HTX-011EXPERIMENTALHTX-011 (bupivacaine/meloxicam), 400 mg/ 12 mg via instillation.
Group 6: Bupivacaine HClACTIVE_COMPARATORBupivacaine HCl without epinephrine, 50 mg via nerve block.
Group 7: Saline PlaceboPLACEBO_COMPARATORSaline placebo via nerve block.
Cohort 1, Group 1: HTX-011EXPERIMENTALHTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via instillation
Cohort 1, Group 2: HTX-011EXPERIMENTALHTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via injection and instillation (combination)
Cohort 1, Group 3: Saline PlaceboPLACEBO_COMPARATORSaline placebo via injection
Cohort 1, Group 4: Bupivacaine HCIACTIVE_COMPARATORBupivacaine HCl without epinephrine, 125 mg via injection
Cohort 2, Group 1: HTX-011EXPERIMENTALHTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation
Cohort 2, Group 2: HTX-011 + RopivacaineEXPERIMENTALHTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation; Ropivacaine, 50 mg via injection
Cohort 2, Group 3: Saline PlaceboPLACEBO_COMPARATORSaline placebo via injection
Cohort 2, Group 4: Bupivacaine HCIACTIVE_COMPARATORBupivacaine HCl without epinephrine, 125 mg via injection
Part A, Cohort AEXPERIMENTALHTX-011 (bupivacaine/meloxicam), 200 mg/6 mg by injection.
Part A, Cohort BEXPERIMENTALHTX-011(bupivacaine/meloxicam), 400 mg/12 mg by injection.
Part A, Cohort CEXPERIMENTALHTX-011 (bupivacaine/meloxicam), 200 mg/6 mg by instillation.
Part A, Cohort DEXPERIMENTALHTX-011 (bupivacaine/meloxicam), 400 mg/12 mg by instillation.
Part A, Cohort EEXPERIMENTALHTX-011 (bupivacaine/meloxicam), 400 mg/12 mg by injection and instillation (combination).
Part A, Cohort FPLACEBO_COMPARATORSaline placebo by injection.
Part B, Cohort AEXPERIMENTALHTX-011A (bupivacaine/meloxicam), 200 mg/6 mg by injection.
Part B, Cohort BEXPERIMENTALHTX-011A (bupivacaine/meloxicam) 400 mg12 mg by injection.
Part B, Cohort CEXPERIMENTALHTX-011B (bupivacaine/meloxicam), 200 mg/6 mg by injection.
Part B, Cohort DEXPERIMENTALHTX-011B (bupivacaine/meloxicam), 400 mg/12 mg by injection.
Part B, Cohort EPLACEBO_COMPARATORSaline placebo by injection.
Part C, Cohort AEXPERIMENTALHTX-002, 200 mg by injection or instillation.
Part B, Cohort FEXPERIMENTALHTX-002, 400 mg by injection or instillation.
Part C, Cohort BEXPERIMENTALHTX-011B (bupivacaine/meloxicam), 200 mg/6 mg by instillation.
Part B, Cohort GEXPERIMENTALHTX-011B (bupivacaine/meloxicam), 400 mg/12 mg by instillation.
Part C, Cohort CPLACEBO_COMPARATORSaline placebo by instillation.
Part C, Cohort DACTIVE_COMPARATORBupivacaine HCI (Marcaine), 75 mg by injection.
Part D, Cohort AEXPERIMENTALHTX-011B (bupivacaine/meloxicam), 400 mg/13 mg via a combination of injection and instillation.
Part E, Cohort AEXPERIMENTALHTX-009, 12 mg by injection and instillation (combination).
Part F, Cohort AEXPERIMENTALHTX-011B (bupivacaine/meloxicam), 300 mg/9 mg by instillation.
Part F, Cohort BEXPERIMENTALBupivacaine HCI (Marcaine), 75 mg by injection.
Part F, Cohort CPLACEBO_COMPARATORSaline placebo by injection.
HTX-011EXPERIMENTALEvaluate the analgesic efficacy of HTX-011
PlaceboPLACEBO_COMPARATORSaline

Interventions

NameTypeDescription
HTX-011DRUGDual-acting local anesthetic. Dose 1.
IbuprofenDRUGNSAID.
AcetaminophenDRUGAnalgesic.
CelecoxibDRUGNSAID.
+/- Bupivacaine HClDRUGLocal anesthetic.
Luer Lock ApplicatorDEVICEApplicator for instillation.
Saline PlaceboDRUGSaline placebo by instillation
Bupivacaine HClDRUGBupivacaine HCl without epinephrine, 50 mg by injection
Luer-lock applicatorDEVICEApplicator for instillation
Vial access deviceDEVICEDevice for withdrawal of drug product
Bupivacaine HCI without epinephrineDRUG100 mg administered via injection into the surgical site.
aprepitantDRUGAprepitant, three single doses of aprepitant will be administered orally.
KetorolacDRUGIntraoperative IV ketorolac.
Bupivacaine HCl without epinephrineDRUGBupivacaine HCl without epinephrine, 50 mg via nerve block.
Bupivicaine HClDRUGBupivacaine HCl without epinephrine
RopivacaineDRUGRopivacaine, via injection
PlaceboDRUGSaline placebo by injection.
HTX-002DRUGHTX-002, by injection or instillation (pooled).
Bupivacaine HCI (Marcaine)DRUGBupivacaine HCI (Marcaine) by injection.
HTX-011ADRUGHTX-011A (bupivacaine/meloxicam) by injection.
HTX-011BDRUGHTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.
HTX-009DRUGHTX-009 by injection and instillation (combination).
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: * Is scheduled to undergo primary unilateral TKA under spinal anesthesia. * Has not previously undergone TKA in either knee. * Has an American Society of Anesthesiologists (ASA) Physical Status of I, II, or III. * Is able to walk at least 20 feet with optional use of a 4-legged ...

Countries:United StatesBelgium
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMAug 17, 2026NCT02471898TRIAL_REMOVED: changed
MEDIUMAug 17, 2026NCT02471898TRIAL_REMOVED: changed
MEDIUMAug 17, 2026NCT02471898TRIAL_REMOVED: changed
MEDIUMJul 5, 2026NCT03907176TRIAL_REMOVED: changed
MEDIUMJul 5, 2026NCT03907176TRIAL_REMOVED: changed
MEDIUMJul 5, 2026NCT03907176TRIAL_REMOVED: changed

Frequently asked questions about HTX-011

What is HTX-011 used for?

HTX-011 is an investigational small molecule being developed for post-operative pain and analgesia. It is designed to provide pain relief following surgical procedures. The drug is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.

Who makes HTX-011?

HTX-011 is being developed by Heron Therapeutics, Inc., a biopharmaceutical company. Heron Therapeutics is publicly traded under the ticker symbol HRTX on the NASDAQ stock exchange.

What phase is HTX-011 in?

HTX-011 is in Phase 3 clinical development for post-operative pain and analgesia. The drug is investigational and has not been approved by the FDA. It has completed seven clinical trials, including Phase 3 studies, with a total enrollment of 1,962 participants.

What clinical trials has HTX-011 been in?

HTX-011 has been studied in several clinical trials, including NCT02471898 for post-bunionectomy analgesia, NCT03907176 for post-herniorrhaphy pain, NCT03955211 for pain after caesarean section, and NCT03974932 for total knee arthroplasty. All trials have been completed.

Is HTX-011 the same as ZYNRELEF?

HTX-011 is the investigational name for the drug that Heron Therapeutics has also marketed under the brand name ZYNRELEF. ZYNRELEF is the trade name for the bupivacaine and meloxicam extended-release solution used for postoperative analgesia.